J E Souness1, D Aldous, C Sargent. Show Affiliations » 1. Discovery Biology 1 (JA3-1), Aventis Pharma Ltd., Dagenham Research Centre, Rainham Road South, Dagenham, RM10 7XS, Essex, UK. john.souness@aventis.com
Abstract
Mesh: See more » 3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors3',5'-Cyclic-AMP Phosphodiesterases/physiologyAnimalsAnti-Inflammatory Agents/chemistryAnti-Inflammatory Agents/pharmacologyAnti-Inflammatory Agents/therapeutic useAutoimmune Diseases/drug therapyCyclic Nucleotide Phosphodiesterases, Type 4Cyclohexanecarboxylic Acids/pharmacologyCyclohexanecarboxylic Acids/therapeutic useDermatologic Agents/pharmacologyDermatologic Agents/therapeutic useHumansLung Diseases/drug therapyNitrilesPhosphodiesterase Inhibitors/chemistryPhosphodiesterase Inhibitors/pharmacologyPhosphodiesterase Inhibitors/therapeutic use
Substances: See more » Anti-Inflammatory AgentsCyclohexanecarboxylic AcidsDermatologic AgentsNitrilesPhosphodiesterase InhibitorsCilomilast3',5'-Cyclic-AMP PhosphodiesterasesCyclic Nucleotide Phosphodiesterases, Type 4
Year: 2000 PMID: 10878287 DOI: 10.1016/s0162-3109(00)00185-5
Source DB: PubMed Journal: Immunopharmacology ISSN: 0162-3109